JNJ 63682931
Alternative Names: Ad26.HPV18; HPV18 Ad26-vectored vaccine; JNJ-63682931Latest Information Update: 11 Nov 2021
At a glance
- Originator Janssen Vaccines and Prevention B.V
- Developer Bavarian Nordic; Janssen Vaccines and Prevention B.V
- Class Antivirals; Papillomavirus vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Human papillomavirus infections
Most Recent Events
- 15 Oct 2020 Janssen Vaccines & Prevention terminates phase I/II trial in Human papillomavirus infections in Belgium and USA due to low enrolment and increasing COVID restrictions (IM) (NCT03610581)
- 27 Sep 2018 Phase-I/II clinical trials in Human papillomavirus infections in USA (IM) (NCT03610581)
- 03 Aug 2018 Janssen Vaccines & Prevention and Bavarian Nordic plans a first-in-man phase I/IIa trial for Human papillomavirus infections (Combination therapy) in USA in August 2018 (NCT03610581) (EudraCT2018-000200-41)